ACM
ADAR1 Capital Management Portfolio holdings
AUM
$616M
1-Year Return
26.77%
This Quarter Return
+12.59%
1 Year Return
+26.77%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$366M
AUM Growth
+$143M
(+64%)
Cap. Flow
+$97.7M
Cap. Flow
% of AUM
26.67%
Top 10 Holdings %
Top 10 Hldgs %
59.33%
Holding
282
New
118
Increased
36
Reduced
44
Closed
29
Top Buys
| 1 |
Alpha Architect 1-3 Month Box ETF
BOXX
|
$33.9M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$25.5M |
| 3 |
Protagonist Therapeutics
PTGX
|
$16.9M |
| 4 |
Roivant Sciences
ROIV
|
$16.2M |
| 5 |
Cytokinetics
CYTK
|
$15.9M |
Top Sells
| 1 |
Keros Therapeutics
KROS
|
$23.2M |
| 2 |
Viking Therapeutics
VKTX
|
$19.7M |
| 3 |
Royalty Pharma
RPRX
|
$18.2M |
| 4 |
Merck
MRK
|
$7.09M |
| 5 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$6.35M |
Sector Composition
| 1 | Healthcare | 82.64% |
| 2 | Communication Services | 1.24% |
| 3 | Financials | 0.78% |
| 4 | Materials | 0.59% |
| 5 | Consumer Discretionary | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
126
Ionis Pharmaceuticals
IONS
$9.46B
| $126K | 0.03% |
+2,900
| New | +$126K |
|
127
Taysha Gene Therapies
TSHA
$889M
| $125K | 0.03% |
43,500
-165,500
| -79% | -$475K |
|
128
Forte Biosciences
FBRX
$136M
| $119K | 0.03% |
+6,820
| New | +$119K |
|
129
KalVista Pharmaceuticals
KALV
$765M
| $119K | 0.03% |
+10,000
| New | +$119K |
|
130
Exact Sciences
EXAS
$9.73B
| $117K | 0.03% |
+1,700
| New | +$117K |
|
131
Organon & Co
OGN
$2.52B
| $113K | 0.03% |
+6,000
| New | +$113K |
|
132
Amylyx Pharmaceuticals
AMLX
$887M
| $110K | 0.03% |
38,858
-38,700
| -50% | -$110K |
|
133
JD.com
JD
$43.9B
| $110K | 0.02% |
+4,000
| New | +$110K |
|
134
Four Leaf Acquisition Corp
FORL
| $107K | 0.02% |
10,000
| – | – |
|
135
Structure Therapeutics
GPCR
$1.14B
| $107K | 0.02% |
2,500
-1,500
| -38% | -$64.3K |
|
|
SLRN
136
DELISTED
ACELYRIN
SLRN
| $101K | 0.02% |
15,021
+8,021
| +115% | +$54.1K |
|
|
LBPH
137
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
| $98.9K | 0.02% |
4,580
+3,780
| +473% | +$81.6K |
|
|
KCGI
138
DELISTED
Kensington Capital Acquisition Corp. V
KCGI
| $97.6K | 0.02% |
9,000
| – | – |
|
139
Lexaria Bioscience
LEXX
$18.9M
| $96.7K | 0.02% |
26,626
+25,000
| +1,538% | +$90.8K |
|
140
NextCure
NXTC
$13.2M
| $95.9K | 0.02% |
3,585
-1,450
| -29% | -$38.8K |
|
141
Bausch + Lomb
BLCO
$5.16B
| $91.7K | 0.02% |
5,300
+1,800
| +51% | +$31.1K |
|
142
CG Oncology
CGON
$2.36B
| $90K | 0.02% |
+2,050
| New | +$90K |
|
143
Altria Group
MO
$112B
| $87.2K | 0.02% |
2,000
-4,000
| -67% | -$174K |
|
144
Mitek Systems
MITK
$441M
| $79K | 0.02% |
5,600
-2,000
| -26% | -$28.2K |
|
|
NNAGU
145
DELISTED
99 Acquisition Group Inc. Unit
NNAGU
| $78.7K | 0.02% |
7,500
| – | – |
|
|
AITRU
146
DELISTED
AI TRANSPORTATION ACQUISITION CORP Unit
AITRU
| $78.2K | 0.02% |
7,500
| – | – |
|
147
Iovance Biotherapeutics
IOVA
$796M
| $74.1K | 0.02% |
5,000
| – | – |
|
148
Adicet Bio
ACET
$59.4M
| $73.4K | 0.02% |
+31,229
| New | +$73.4K |
|
149
Howard Hughes
HHH
$4.62B
| $72.6K | 0.02% |
1,049
-2,098
| -67% | -$145K |
|
150
Jasper Therapeutics
JSPR
$43.7M
| $70.6K | 0.02% |
+2,406
| New | +$70.6K |
|